<DOC>
	<DOC>NCT02220348</DOC>
	<brief_summary>The purpose of this study is to determine the amount of linaclotide and its active metabolite (MM-419447) excreted in breast milk after multiple, once daily doses of linaclotide (145 μg or 290 μg) in lactating women receiving the drug therapeutically.</brief_summary>
	<brief_title>A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Be a lactating female who has been actively breastfeeding or pumping for at least 4 weeks Be already taking linaclotide therapeutically for Irritable Bowel Syndrome with Constipation (IBSC) or Chronic Idiopathic Constipation (CIC) Weaning must not be underway Be willing to breastfeed or pump regularly during the study to maintain milk supply and discontinue breastfeeding for the 24hour period of breast milk collection Clinically significant disease state in any body system, except for the indication being treated with linaclotide Any structural abnormality of the gastrointestinal (GI) tract, or a disease or condition that can affect GI motility Participation in any other clinical investigation using an experimental drug within 90 days</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>